The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Strategies to Inhibit Myc and Their Clinical Applicability
Open accessAbstract
Myc is an oncogene deregulated in most-perhaps all-human cancers. Each Myc family member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance. Myc is recognized as a "most wanted" target for cancer therapy, but has for many years been considered undruggable, mainly due to its nuclear localization, lack of a defined ligand binding site, and physiological function essential to the maintenance of normal tissues. The challenge of identifying a pharmacophore capable of overcoming these hurdles is reflected in the current absence of a clinically-viable Myc inhibitor. The first attempts to inhibit Myc used antisense technology some three decades ago, followed by small molecule inhibitors discovered through "classical" compound library screens. Notable breakthroughs proving the feasibility of systemic Myc inhibition were made with the Myc dominant negative mutant Omomyc, showing both the great promise in targeting this infamous oncogene for cancer treatment as well as allaying fears about the deleterious side effects that Myc inhibition might have on normal proliferating tissues. During this time many other strategies have appeared in an attempt to drug the undruggable, including direct and indirect targeting, knockdown, protein/protein and DNA interaction inhibitors, and translation and expression regulation. The inhibitors range from traditional small molecules to natural chemicals, to RNA and antisense, to peptides and miniproteins. Here, we briefly describe the many approaches taken so far, with a particular focus on their potential clinical applicability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 855
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Self-citationCyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Drygin, D., Lin, A., Bliesath, J., Ho, C. B., O'Brien, S. E., Proffitt, C., Omori, M., Haddach, M., Schwaebe, M. K., Siddiqui-Jain, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1728 · Cited by 618
MYC, Metabolism, Cell Growth, and Tumorigenesis
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 602
DNA tetraplex formation in the control region of c-myc
Simonsson, T. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.5.1167 · Cited by 598
Quadruplex Nucleic Acids as Novel Therapeutic Targets
Neidle, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01835 · Cited by 582
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551
BET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545
Soucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B., & Evan, G. I. (2007) · Nature Medicine · doi:10.1038/nm1649 · Cited by 507
Self-citationTranscriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., et al. (2012) · Science · doi:10.1126/science.1212728 · Cited by 433
Low molecular weight inhibitors of Myc–Max interaction and function
Yin, X., Giap, C., Lazo, J. S., & Prochownik, E. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206641 · Cited by 428
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D. C., Rezai, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 420
The Life Cycle of C-Myc: From Synthesis to Degradation
Sears, R. C. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1145 · Cited by 417
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408 · cited 3×
“In tumor cells however, the cellular levels of Myc become independent from such signaling and regulation, and the resulting exacerbated Myc function drives intracellular and extracellular transcription programs that allow tumors to grow and thrive (Soucek and Evan, 2002; Dang, 2012; Whitfield and Soucek, 2012; Conacci…”
BackgroundExploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
Berg, T., Cohen, S. B., Desharnais, J., Sonderegger, C., Maslyar, D. J., Goldberg, J., Boger, D. L., & Vogt, P. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062036999 · Cited by 326
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Targeting MYC Expression through G-Quadruplexes
Brooks, T. A., & Hurley, L. H. (2010) · Genes & Cancer · doi:10.1177/1947601910377493 · Cited by 301
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
Self-citationBrockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.005 · Cited by 299
Brooks, T. A., & Hurley, L. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2733 · Cited by 294
Stabilization of G-Quadruplex DNA and Down-Regulation of Oncogene c-myc by Quindoline Derivatives
Ou, T.-M., Lu, Y.-J., Zhang, C., Huang, Z.-S., Wang, X.-D., Tan, J.-H., Chen, Y., Ma, D.-L., Wong, K.-Y., Tang, J. C.-O., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0610088 · Cited by 288
A unique glucose-dependent apoptotic pathway induced by c-Myc
Shim, H., Chun, Y. S., Lewis, B. C., & Dang, C. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1511 · Cited by 286
Deregulated MYC expression induces dependence upon AMPK-related kinase 5
Liu, L., Ulbrich, J., Müller, J., Wüstefeld, T., Aeberhard, L., Kress, T. R., Muthalagu, N., Rycak, L., Rudalska, R., Moll, R., et al. (2012) · Nature · doi:10.1038/nature10927 · Cited by 276
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Campaner, S., Doni, M., Hydbring, P., Verrecchia, A., Bianchi, L., Sardella, D., Schleker, T., Perna, D., Tronnersjö, S., Murga, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2004 · Cited by 251
Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics
Chen, B.-J., Wu, Y.-L., Tanaka, Y., & Zhang, W. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.10190 · Cited by 248
Clinical trials for BET inhibitors run ahead of the science
Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247
Alternative Translation of the Proto-oncogene c-mycby an Internal Ribosome Entry Site
Nanbru, C., Lafon, I., Audigier, S., Gensac, M.-C., Vagner, S., Huez, G., & Prats, A.-C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32061 · Cited by 243
den Hollander, J., Rimpi, S., Doherty, J. R., Rudelius, M., Buck, A., Hoellein, A., Kremer, M., Graf, N., Scheerer, M., Hall, M. A., et al. (2010) · Blood · doi:10.1182/blood-2009-11-251074 · Cited by 242
Functional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H. R., Lilischkis, R., Hein, N., Wu, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900121106 · Cited by 225
Drugging Undruggable Molecular Cancer Targets
Lazo, J. S., & Sharlow, E. R. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 224
Therapeutic Strategies to Inhibit MYC
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 222
Design and properties of a Myc derivative that efficiently homodimerizes
Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., & Nasi, S. (1998) · Oncogene · doi:10.1038/sj.onc.1202199 · Cited by 221
Self-citationDeregulated Myc Requires MondoA/Mlx for Metabolic Reprogramming and Tumorigenesis
Carroll, P. A., Diolaiti, D., McFerrin, L., Gu, H., Djukovic, D., Du, J., Cheng, P. F., Anderson, S., Ulrich, M., Hurley, J. B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.024 · Cited by 207
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 202
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
Annibali, D., Whitfield, J. R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzàlez-Juncà, A., Sodir, N. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5632 · Cited by 200
Self-citationCDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
Huang, C.-H., Lujambio, A., Zuber, J., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 198
Improved low molecular weight Myc-Max inhibitors
Wang, H., Hammoudeh, D. I., Follis, A. V., Reese, B. E., Lazo, J. S., Metallo, S. J., & Prochownik, E. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0005 · Cited by 190
Prochownik, E. V., Kukowska, J., & Rodgers, C. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.9.3683 · Cited by 189
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183
Endogenous Myc maintains the tumor microenvironment
Sodir, N. M., Swigart, L. B., Karnezis, A. N., Hanahan, D., Evan, G. I., & Soucek, L. (2011) · Genes & Development · doi:10.1101/gad.2038411 · Cited by 179
Self-citationYang, D., Liu, H., Goga, A., Kim, S., Yuneva, M., & Bishop, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008366107 · Cited by 177
c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle
Wang, H., Mannava, S., Grachtchouk, V, Zhuang, D., Soengas, M. S., Gudkov, A. V., Prochownik, E. V., & Nikiforov, M. A. (2008) · Oncogene · doi:10.1038/sj.onc.1210823 · Cited by 174
Brown, R. V., Danford, F. L., Gokhale, V., Hurley, L. H., & Brooks, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274720 · Cited by 172
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4213 · Cited by 170
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing
Nilson, K. A., Guo, J., Turek, M. E., Brogie, J. E., Delaney, E., Luse, D. S., & Price, D. H. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.032 · Cited by 169
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 161
Wu, P., Ma, D., Leung, C., Yan, S., Zhu, N., Abagyan, R., & Che, C. (2009) · Chemistry – A European Journal · doi:10.1002/chem.200901943 · Cited by 161
Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tatò, F., & Nasi, S. (2002) · PubMed · Cited by 160
Self-citationBPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis
Richart, L., Pau, E. C. D. S., Rio‐Machín, A., de Andrés, M. P., Cigudosa, J. C., Lobo, V. J. S.-A., & Real, F. X. (2016) · Nature Communications · doi:10.1038/ncomms10153 · Cited by 156
Prochownik, E. V., & Vogt, P. K. (2010) · Genes & Cancer · doi:10.1177/1947601910377494 · Cited by 155
Conde, J., Tian, F., Hernández, Y., Bao, C., Cui, D., Janssen, K., Ibarra, M. R., Baptista, P. V., Stoeger, T., & de la Fuente, J. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.041 · Cited by 154
Inhibitor of MYC identified in a Kröhnke pyridine library
Hart, J. R., Garner, A. L., Yu, J., Ito, Y., Sun, M., Ueno, L. A., Rhee, J., Baksh, M. M., Stefan, E., Hartl, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319488111 · Cited by 150
Sun, K., Atoyan, R., Borek, M. A., DellaRocca, S., Samson, M., Ma, A. W., Xu, G.-X., Patterson, T. D., Tuck, D. P., Viner, J. L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0390 · Cited by 143
Garcia, P. L., Miller, A. L., Kreitzburg, K. M., Gamblin, T. L., Christein, J. D., Heslin, M. J., Arnoletti, J. P., Richardson, J. H., Chen, D., Hanna, C. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.126 · Cited by 141
Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M. D., Evan, G. I., Soucek, L., & Nasi, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022284 · Cited by 136
Self-citationEfficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133
Peter, S., Bultinck, J., Myant, K., Jaenicke, L. A., Walz, S., Müller, J., Gmachl, M., Treu, M., Boehmelt, G., Ade, C. P., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403927 · Cited by 131
Felsenstein, K. M., Saunders, L. B., Simmons, J. K., Leon, E. C., Calabrese, D. R., Zhang, S., Michalowski, A. M., Gareiss, P. C., Mock, B. A., & Schneekloth, J. S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00577 · Cited by 129
Wiegering, A., Uthe, F. W., Jamieson, T. J., Ruoss, Y., Hüttenrauch, M., Küspert, M., Pfann, C., Nixon, C., Herold, S., Walz, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1040 · Cited by 123
Guo, J., Parise, R. A., Joseph, E., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0774-y · Cited by 123
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
Clausen, D. M., Guo, J., Parise, R. A., Beumer, J. H., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170555 · Cited by 117
Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc
Chen, Y., Niu, X., Jin, F., Liu, Z., Jin, C., & Lai, L. (2016) · Scientific Reports · doi:10.1038/srep22298 · Cited by 117
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Oddo, J., Vitek, M. P., Lopez, C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0542 · Cited by 114
Devi, G. R., Beer, T. M., Corless, C. L., Arora, V., Weller, D. L., & Iversen, P. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2091 · Cited by 111
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Moreno, P. M. D., & Pêgo, A. P. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00087 · Cited by 111
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 111
Oncolytic virus therapy for cancer: the first wave of translational clinical trials
Patel, M. R., & Kratzke, R. A. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.010 · Cited by 105
Bidwell, G. L., Perkins, E., Hughes, J. D., Khan, M., James, J. R., & Raucher, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055104 · Cited by 102
Huang, H., Weng, H., Wang, L., Yu, C.-H., Huang, Q.-J., Zhao, P., Wen, J.-Z., Zhou, H., & Qu, L. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0066 · Cited by 100
Perturbation of the c-Myc–Max Protein–Protein Interaction via Synthetic α-Helix Mimetics
Jung, K., Wang, H., Teriete, P., Yap, J. L., Chen, L., Lanning, M. E., Hu, A., Lambert, L. J., Holien, T., Sundan, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501440q · Cited by 96
A credit-card library approach for disrupting protein–protein interactions
Xu, Y., Shi, J., Yamamoto, N., Moss, J. A., Vogt, P. K., & Janda, K. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.052 · Cited by 93
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
Bid, H. K., Phelps, D. A., Xaio, L., Guttridge, D. C., Lin, J., London, C. A., Baker, L. H., Mo, X. M., & Houghton, P. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0567 · Cited by 92
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Koh, C. M., Sabò, A., & Guccione, E. (2016) · BioEssays · doi:10.1002/bies.201500134 · Cited by 91
Zhang, Y., Peng, L., Mumper, R. J., & Huang, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.050 · Cited by 90
Macarulla, T. M., Cervantes, A. M. R., Élez, E., Rodríguez-Braun, E., Baselga, J. M., Roselló, S., Sala, G., Blasco, I., Danaee, H., Lee, Y., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0299 · Cited by 90
Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer
Stellas, D., Szabolcs, M. J., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., & Efstratiadis, A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju320 · Cited by 87
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
Fiorentino, F. P., Tokgün, P. E., Solé‐Sánchez, S., Giampaolo, S., Tokgün, O., Jauset, T., Kohno, T., Perucho, M., Soucek, L., & Yokota, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8826 · Cited by 87
Self-citationTumor microenvironment: becoming sick of Myc
Whitfield, J. R., & Soucek, L. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0860-x · Cited by 85
Self-citationTargeting RNA polymerase I to treat MYC-driven cancer
Poortinga, G., Quinn, L. M., & Hannan, R. D. (2014) · Oncogene · doi:10.1038/onc.2014.13 · Cited by 83
Pharmacophore identification of c-Myc inhibitor 10074-G5
Yap, J. L., Wang, H., Hu, A., Chauhan, J., Jung, K.-Y., Gharavi, R. B., Prochownik, E. V., & Fletcher, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.013 · Cited by 83
Giorello, L., Clerico, L., Pescarolo, M. P., Vikhanskaya, F., Salmona, M., Colella, G., Bruno, S., Mancuso, T., Bagnasco, L., Russo, P., et al. (1998) · PubMed · Cited by 82
Mo, H., & Arsenian‐Henriksson, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601418103 · Cited by 81
Omomyc expression in skin prevents Myc-induced papillomatosis
Soucek, L., Nasi, S., & Evan, G. I. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401443 · Cited by 77
Self-citationHogg, S. J., Newbold, A., Vervoort, S. J., Cluse, L. A., Martin, B. P., Gregory, G. P., Lefebure, M., Vidacs, E., Tothill, R. W., Bradner, J. E., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0924 · Cited by 77
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
Munshi, H., Abedin, S., & Boddy, C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100515 · Cited by 71
Arora, V., Knapp, D. C., Smith, B. L., Statdfield, M., Stein, D. A., Reddy, M. T., Weller, D. D., & Iversen, P. L. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35371-6 · Cited by 71
Synthetic Lethal Screens as a Means to Understand and Treat MYC-Driven CancersPreprint
Cermelli, S., Jang, I. S., Bernard, B. M., & Grandori, C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014209 · Cited by 71
Thomas, L. R., Foshage, A. M., Weissmiller, A. M., & Tansey, W. P. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1216 · Cited by 69
Modified gold nanoparticles for intracellular delivery of anti-liver cancer siRNA
Shaat, H., Mostafa, A., Moustafa, M., Gamal‐Eldeen, A. M., Emam, A. N., El‐Hussieny, E. A., & ElHefnawi, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.051 · Cited by 67
Jain, S., Wang, X., Chang, C., Ibarra-Drendall, C., Wang, H., Zhang, Q., Brady, S. W., Li, P., Zhao, H., Dobbs, J. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2345 · Cited by 64
Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma
Soucek, L., Buggy, J. J., Kortlever, R. M., Adimoolam, S., Allende, H., Salcedo, M. T., Swigart, L. B., & Evan, G. I. (2011) · Neoplasia · doi:10.1593/neo.11980 · Cited by 62
Self-citationStabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function
Jiang, H., Bower, K. E., Beuscher, A. E., Zhou, B., Bobkov, A. A., Olson, A. J., & Vogt, P. K. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054858 · Cited by 62
Resetting cancer stem cell regulatory nodes upon MYC inhibition
Galardi, S., Savino, M., Scagnoli, F., Pellegatta, S., Pisati, F., Zambelli, F., Illi, B., Annibali, D., Beji, S., Orecchini, E., et al. (2016) · EMBO Reports · doi:10.15252/embr.201541489 · Cited by 61
Sklar, M. D., Thompson, E., Welsh, M. J., Liebert, M., Harney, J., Grossman, H. B., Smith, M. J., & Prochownik, E. V. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.7.3699 · Cited by 60
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
Ambrosini, G., Sawle, A., Musi, E., & Schwartz, G. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5179 · Cited by 60
Soodgupta, D., Pan, D., Cui, G., Senpan, A., Yang, X., Lu, L., Weilbaecher, K. N., Prochownik, E. V., Lanza, G. M., & Tomasson, M. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0774-t · Cited by 59
Wang, H., Chauhan, J., Hu, A., Pendleton, K. P., Yap, J. L., Sabato, P. E., Jones, J. W., Perri, M., Yu, J., Cione, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1108 · Cited by 58
Intravesical Instillation of c-MYC Inhibitor KSI-3716 Suppresses Orthotopic Bladder Tumor Growth
Jeong, K., Kim, K., Seo, H.-H., Shin, S.-P., Ahn, K.-O., Ji, M.-J., Park, W. S., Kim, I.-H., Lee, S.-J., & Seo, H. K. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.07.019 · Cited by 55
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids
Wang, H., Teriete, P., Hu, A., Raveendra-Panickar, D., Pendelton, K., Lazo, J. S., Eiseman, J., Holien, T., Misund, K., Oliynyk, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6116 · Cited by 53
Donato, E., Croci, O., Sabò, A., Müller, H., Morelli, M. J., Pelizzola, M., & Campaner, S. (2016) · Leukemia · doi:10.1038/leu.2016.182 · Cited by 53
Chauhan, J., Wang, H., Yap, J. L., Sabato, P. E., Hu, A., Prochownik, E. V., & Fletcher, S. (2014) · ChemMedChem · doi:10.1002/cmdc.201402189 · Cited by 49
Deubiquitinating c-Myc: USP36 steps up in the nucleolus
Sun, X., Sears, R. C., & Dai, M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1093713 · Cited by 48
Shi, X., Mihaylova, V. T., Kuruvilla, L., Chen, F., Viviano, S., Baldassarre, M., Sperandio, D., Martinez, R., Yue, P., Bates, J. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608319113 · Cited by 48
Shapiro, G. I., Dowlati, A., LoRusso, P. M., Eder, J. P., Anderson, A., Do, K. T., Kagey, M. H., Sirard, C. A., Bradner, J. E., & Landau, S. B. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-a49 · Cited by 47
Myc—Is this the oncogene from Hell?
Soucek, L., & Evan, G. I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00077-6 · Cited by 43
Self-citationThe Quest for Targets Executing MYC-Dependent Cell Transformation
Hartl, M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00132 · Cited by 41
Kumar, A., Ito, A., Hirohama, M., Yoshida, M., & Zhang, K. Y. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.030 · Cited by 40
Li, L., Sun, W. Y., Zhang, Z., & Huang, Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.021 · Cited by 39
Prochownik, E. V., Kukowska, J., & Rodgers, C. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.9.3683-3695.1988 · Cited by 39
Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer
Seo, H. K., Ahn, K.-O., Jung, N.-R., Shin, J., Park, W. S., Lee, K. H., Lee, S.-J., & Jeong, K. (2014) · Oncotarget · doi:10.18632/oncotarget.1545 · Cited by 38
MYC, Metabolic Synthetic Lethality, and Cancer
Hsieh, A. L., & Dang, C. V. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_4 · Cited by 38
Myc Overexpression Enhances Apoptosis Induced by Small Molecules
Mo, H., Vita, M. F., Crespin, M., & Arsenian‐Henriksson, M. (2006) · Cell Cycle · doi:10.4161/cc.5.19.3320 · Cited by 37
Ibrutinib in B lymphoid malignancies
Smith, M. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067302 · Cited by 35
Taking a Back Door to Target Myc
Evan, G. I. (2012) · Science · doi:10.1126/science.1217819 · Cited by 34
microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13
Han, H., Chen, Y., Cheng, L., Prochownik, E. V., & Li, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7653 · Cited by 33
c-MYC partners with BPTF in human cancer
Richart, L., Real, F. X., & Lobo, V. J. S.-A. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1152346 · Cited by 29
The Max b-HLH-LZ Can Transduce into Cells and Inhibit c-Myc Transcriptional Activities
Montagne, M., Beaudoin, N., Fortin, D., Lavoie, C. L., Klinck, R., & Lavigne, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032172 · Cited by 28
Perylene side chains modulate G-quadruplex conformation in biologically relevant DNA sequences
Pivetta, C., Lucatello, L., Krapcho, A. P., Gatto, B., Palumbo, M., & Sissi, C. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.068 · Cited by 27
Recent advances in targeting mTOR signaling pathway using small molecule inhibitors
Roohi, A., & Hojjat‐Farsangi, M. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1236112 · Cited by 26
Kipshidze, N. N., Iversen, P. L., OVERLIE, P. A., Dunlap, T., Titus, B. G., Lee, D., Moses, J. W., O'Hanley, P. D., Lauer, M. A., & Leon, M. B. (2007) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2007.04.002 · Cited by 25
Kipshidze, N. N., Porter, T. R., Dangas, G., Yazdi, H. A., Tio, F. O., Xie, F., Hellinga, D. G., Fournadjiev, J. A., Wolfram, R. M., Seabron, R., et al. (2003) · Cardiovascular Radiation Medicine · doi:10.1016/s1522-1865(03)00184-7 · Cited by 21
Wang, H., Ramakrishnan, A., Fletcher, S., & Prochownik, E. V. (2015) · Journal of Biological Methods · doi:10.14440/jbm.2015.54 · Cited by 20
MYC-Mediated Synthetic Lethality for Treating Tumors
Li, X., Zhang, X., Li, X., Xie, W., & Huang, S. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009615666150121162921 · Cited by 19
Sklar, M. D., Thompson, E., Welsh, M. J., Liebert, M., Harney, J., Grossman, H. B., Smith, M. J., & Prochownik, E. V. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.7.3699-3710.1991 · Cited by 16
Helm, F., Kammertoens, T., Lehmann, F., Wilke, A., Bruns, H., Mautner, J., Bornkamm, G. W., & Gerbitz, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077375 · Cited by 11
Cited by
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
“, 2017), (Whitfield et al., 2017), (Aster and Blacklow, 2012), (Takebe et al.”
BackgroundRegulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Self-citationG-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 533
Metadata
- Authors
- Whitfield, J. R., Beaulieu, M.-E., & Soucek, L.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2017-02-23
- Volume
- 5
- Pages
- 10-10
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W2602591481
- Cited by
- 294
- References
- 147
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.